Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

g which the Court will render its final order.  We look forward to a resolution of these next steps and to SIGA's successful commercialization of ST-246, which has the opportunity for additional U.S. government procurement contracts."

Third Quarter Financial ResultsFor the third quarter of 2011 PharmAthene recognized revenue of $5.3 million compared to $6.2 million in the same period of 2010.  Revenues for the most recent quarter consisted of contract funding from the U.S. government for the development of the Company's SparVax™ and Valortim® biodefense programs.  

Revenues for the Company's SparVax™ program were $4.3 million for the three months ended September 30, 2011 compared to $3.8 million for the same period in 2010.  The increase in revenue for the Company's SparVax™ program is primarily attributable to additional work conducted in relation to the technology transfer process for SparVax™ to a US-based contract manufacturer and related milestone payments.

Revenues for the Company's Valortim® program were $0.9 million for the third quarter of 2011 compared to $0.6 million for the same period in 2010. The increase in revenues for SparVax™ and Valortim® during this period was offset by a decrease in Protexia® revenue resulting from the completion of PharmAthene's contract with the Department of Defense (DoD) in 2010.

Research and development expenses were $4.9 million for the quarter ended September 30, 2011 compared to $6.2 million for the same period in 2010.  The year-over-year difference in research and development expenses were primarily due to the decrease in development expenses related to the completion of the bioscavenger contract with the DoD.

General and administrative expenses were $3.3 million and $3.2 million for the quarters ended September 30, 2011 and 2010, respectively.

For the third quarter of 2011 PharmAthene's net loss att
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... PARK, Calif. , March 2, 2015  Asterias ... in the emerging field of regenerative medicine, today announced ... 2014 financial and operating results on Tuesday, March 10, ... The Company will host a conference call and webcast ... / 1:30 p.m. Pacific to discuss the results and ...
(Date:3/2/2015)... Boston, Massachusetts (PRWEB) March 02, 2015 ... legal services, today announced the addition of Debbie Casey ... group’s capabilities in the healthcare space. , ... industry, most of which with Fresenius Medical Care North ... will leverage her extensive experience to work with Outside ...
(Date:2/27/2015)... SUMMERLAND, British Columbia , Feb. 27, ... XON ), a leader in synthetic biology, today announced ... Specialty Fruits (OSF), the pioneering agricultural company behind ... first non-browning apple. Through the acquisition, Intrexon expands its ... more appetizing and convenient for consumers while providing economic ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Outside GC Expands Healthcare Team 2Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... This release is available in Spanish . ... leading in Spain the European project within the VII Framework ... buildings which host large numbers of people, such as sports ... by the management and optimisation of energy in its three ...
... 5, 2011 Sangamo BioSciences, Inc. (Nasdaq: SGMO ... will provide an update on the progress of Sangamo,s ZFP ... strategy at 12:30 pm PT (3:30 pm ET) on Thursday, ... Conference which will be held in San Francisco. ...
... HOUSTON, Jan. 5, 2011 International energy pricing agency ... expansion into US and Canadian wood chip pricing complements ... broader European biomass indexation. " Argus understands ... to be at the forefront, providing transparency to emerging biomass ...
Cached Biology Technology:Tecnalia leads the integration of energy efficiency in sports facilities 2Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference 2Argus Launches North American Wood Chip Price Assessments 2
(Date:2/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD ... a new groundbreaking payment method. Payment accounts may be ... only be accessed if both the speech (the word ...
(Date:2/18/2015)... 2015  Cepheid (NASDAQ: CPHD ) today announced ... and invited investors to participate via webcast. , Cowen ... Tuesday, March 3, 2015 at 11.20 a.m. Eastern Time ... FL Wednesday, March 4, 2015 at 10.25 a.m. ... live webcasts for these events, please visit Cepheid,s website at ...
(Date:2/12/2015)...   MedNet Solutions , a global life ... systems, has recently bolstered its iMedNet™ ... iMedNet as the eClinical solution of ... consultants.  Building on the Program,s existing benefits (including ... co-marketing opportunities), MedNet,s new and improved program provides ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... intimately familiar with the awe-inspiring photos of space shuttle launches ... But how many people have paused for even a second ... a two-week space shuttle mission or are living for months ... book The Astronaut,s Cookbook Tales, Recipes, and More ...
... 13 BIO-key International, Inc. (OTC Bulletin Board: BKYI), ... identification solutions, today reported results for the third quarter ... The Company,s results reflected operating profitability for each quarter ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , As a result of ...
... DALLAS Nov. 12, 2009 UT Southwestern ... to date for basic and patient-oriented research from the ... billion stimulus package President Barack Obama signed into law ... the National Science Foundation (NSF) and the National Institutes ...
Cached Biology News:The astronaut's cookbook 2BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 2BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 3BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 4BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 5BIO-key(R) Reports Fourth Consecutive Quarter of Operating Profitability 6UT Southwestern receives $42 million in Recovery Act stimulus funding 2UT Southwestern receives $42 million in Recovery Act stimulus funding 3
MAb to HSV-2, gG-2 HSV-2 Glycoprotein G-2...
Immunogen for A300-655A was a phosphorylated synthetic peptide, which represented a portion of human RNA Polymerase II (GeneID 5430) around serine 5 of the C-terminal repeat YSPTSPS....
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
MAb to IgG2 (Fc gamma-2) IgG2 (Fc, gamma-2 epitope)...
Biology Products: